- Home
- ZURA vs REFI Comparison
ZURA vs REFI Comparison
Compare ZURA & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- REFI
- Stock Information
- Founded
- ZURA 2022
- REFI 2021
- Country
- ZURA United States
- REFI United States
- Employees
- ZURA N/A
- REFI N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- REFI Real Estate Investment Trusts
- Sector
- ZURA Health Care
- REFI Real Estate
- Exchange
- ZURA Nasdaq
- REFI Nasdaq
- Market Cap
- ZURA 292.1M
- REFI 306.1M
- IPO Year
- ZURA N/A
- REFI 2021
- Fundamental
- Price
- ZURA $2.20
- REFI $16.14
- Analyst Decision
- ZURA Buy
- REFI Buy
- Analyst Count
- ZURA 6
- REFI 2
- Target Price
- ZURA $15.80
- REFI $20.00
- AVG Volume (30 Days)
- ZURA 443.4K
- REFI 85.4K
- Earning Date
- ZURA 11-07-2024
- REFI 11-07-2024
- Dividend Yield
- ZURA N/A
- REFI 11.63%
- EPS Growth
- ZURA N/A
- REFI N/A
- EPS
- ZURA N/A
- REFI 2.00
- Revenue
- ZURA N/A
- REFI $56,860,278.00
- Revenue This Year
- ZURA N/A
- REFI N/A
- Revenue Next Year
- ZURA N/A
- REFI $4.27
- P/E Ratio
- ZURA N/A
- REFI $8.08
- Revenue Growth
- ZURA N/A
- REFI 6.49
- 52 Week Low
- ZURA $2.00
- REFI $14.82
- 52 Week High
- ZURA $6.35
- REFI $17.65
- Technical
- Relative Strength Index (RSI)
- ZURA 25.88
- REFI 58.59
- Support Level
- ZURA $2.71
- REFI $16.12
- Resistance Level
- ZURA $2.81
- REFI $16.27
- Average True Range (ATR)
- ZURA 0.24
- REFI 0.17
- MACD
- ZURA -0.02
- REFI -0.00
- Stochastic Oscillator
- ZURA 3.92
- REFI 60.61
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.